高血压肾病患者凝血指标与同型半胱氨酸β2微球蛋白水平及终末期肾病发生的关系研究

doi:10.3969/j.issn.1006-6233.2025.05.010

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 分析高血压肾病患者凝血指标与同型半胱氨酸(Hcy)、β2微球蛋白(β2-MG)水平及终末期肾病发生的关系。方法: 以2019年8月至2021年8月本院收治的138例高血压肾病患者为观察组,随访3年依据其终末期肾病的发生情况分为终末期肾病组(n=26)和无终末期肾病组(n=112);另选取同期于本院接受检查的高血压未合并肾病患者102例作为对照组。测定所有研究对象的凝血指标[D-二聚体(D-D)、纤维蛋白原(Fib)、纤维蛋白原降解产物(FDP)]、Hcy、β2-MG水平,以Pearson相关分析高血压肾病患者D-D、Fib、FDP水平与Hcy、β2-MG水平的相关性,以Logistic回归分析高血压肾病患者D-D、Fib、FDP水平与终末期肾病发生的关联性。结果: 观察组的血清D-D、Fib、FDP、Hcy、β2-MG水平高于对照组(P<0.05);终末期肾病组的血清D-D、Fib、FDP、Hcy、β2-MG水平高于无终末期肾病组(P<0.05)。相关性分析显示,高血压肾病患者血清D-D、Fib、FDP水平与Hcy、β2-MG水平呈正相关(r=0.771,0.795;0.568,0.619;0.545,0.591,P<0.05);高血压肾病患者D-D、Fib、FDP水平是终末期肾病的发生的独立危险因素(P<0.05)。结论: 高血压肾病患者的D-D、Fib、FDP水平与Hcy、β2-MG水平及终末期肾病均呈正相关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	白若玥
	李琴

关键词 ：高血压肾病, 终末期肾病, 凝血指标, 同型半胱氨酸, β2微球蛋白, 相关性

Abstract：Objective: To analyze the correlation between coagulation indexes and homocysteine (Hcy), β2-microglobulin (β2-MG) and occurrence of end-stage renal disease (ESRD) in patients with hypertensive nephropathy (HN). Methods: A total of 138 patients with HN in the hospital from August 2019 to August 2021 were selected as the study group. According to the occurrence of ESRD after 3 years of follow-up, the above patients were divided into ESRD group (n=26) and non-ESRD group (n=112). In addition, 102 hypertensive patients without nephropathy who received examination in the hospital during the same period were included in the control group. The levels of coagulation indexes [D-dimer (D-D), fibrinogen (Fib), fibrinogen degradation product (FDP)], Hcy and β2-MG were measured among all study subjects. The correlation between D-D, Fib and FDP levels and Hcy and β2-MG levels in hypertensive nephropathy patients was analyzed by Pearson correlation, and the correlation between D-D, Fib and FDP levels and the occurrence of end-stage nephropathy in hypertensive nephropathy patients was analyzed by Logistic regression. Results: The levels of serum D-D, Fib, FDP, Hcy and β2-MG in the study group were higher than those in the control group (P<0.05). Serum D-D, Fib, FDP, Hcy and β2-MG levels were higher in the ESRD group than those in the non-ESRD group (P<0.05). Correlation analysis indicated that serum D-D, Fib and FDP levels were positively correlated with Hcy and β2-MG levels in patients with HN (r=0.771, 0.795; 0.568, 0.619; 0.545,0.591, P<0.05). The levels of D-D, Fib and FDP in hypertensive nephropathy patients were independent risk factors for end-stage nephropathy (P<0.05). Conclusion: The levels of D-D, Fib and FDP in hypertensive nephropathy patients were positively correlated with the levels of Hcy, β2-MG and end-stage nephropathy.

Key words： Hypertensive nephropathy End-stage renal disease Coagulation indexes Homocysteine β2-microglobulin Correlation

基金资助:陕西省自然科学基础研究计划项目,(编号:2024JC-YBQN-0819)

通讯作者: 李琴

引用本文:

白若玥, 李琴. 高血压肾病患者凝血指标与同型半胱氨酸β2微球蛋白水平及终末期肾病发生的关系研究[J]. 河北医学, 2025, 31(5): 761-765.
BAI Ruoyue, LI Qin. Study on Correlation between Coagulation Indexes and Homocysteine β2 Microglobulin and Occurrence of End-Stage Renal Disease in Patients with Hypertensive Nephropathy. HeBei Med, 2025, 31(5): 761-765.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.05.010 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I5/761

[1] Peng Z,Xu Q,Hu W,et al.Review on molecular mechanism of hypertensive nephropathy[J].Curr Pharm Des,2023,29(32):2568-2578.
[2] 左君秋,余燕燕,周红霞,等.凝血指标联合血清单核细胞趋化蛋白-1对慢性肾脏病患者急性肾损伤的预测价值[J].中国血液净化,2024,23(4):277-281.
[3] Lin L,Wang C,Ren J,et al.A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension[J].Hypertens,2023,41(8):1306-1312.
[4] Xu Y,Wu J,Gao L,et al.α-Mangostin reduces hypertension in spontaneously hypertensive rats and inhibits EMT and fibrosis in Ang II-induced HK-2 cells[J].Int Med Sci,2024,21(9):1681-1688.
[5] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,中华医学会《中华全科医师杂志》编辑委员会,等.高血压基层诊疗指南(实践版·2019)[J].中华全科医师杂志,2019,18(8):723-731.
[6] Liu L,Zhou X,Yan H,et al.Symptom relief for patients with senile hypertension[J].Asian Surg,2023,46(12):6089-6090.
[7] Zhang Y,Zhang N,Zou Y,et al.Deacetylation of septin4 by SIRT2 (silent mating type information regulation 2 homolog-2) mitigates damaging of hypertensive nephropathy[J].Circ Res,2023,132(5):601-624.
[8] 张军,方利,郑小玲,等.透析模式对终末期肾病患者心血管结局影响的研究进展[J].重庆医学,2023,52(21):3314-3318.
[9] 丁瑾,传小文.瑞舒伐他汀联合缬沙坦对老年原发性高血压早期肾损伤患者肾功能及凝血功能的影响[J].血栓与止血学,2021,27(4):632-633,636.
[10] Li Y,Zhong X,Yang F.Silencing HE4 alleviates the renal fibrosis in lupus nephritis mice by regulating the C3/MMPs/prss axis[J].Naunyn Schmiedebergs Arch Pharmacol,2024,397(7):4823-4831.
[11] 贺松敏,王宝喜,江杨阳,等.终末期肾病维持性血液透析患者β2-MG、EOS水平与颈动脉粥样硬化及预后的关系[J].现代生物医学进展,2023,23(11):2178-2182.
[12] 陈晨,杨润,冯俊琦,等.成人肝移植术后急性肾损伤的发生与术后凝血功能变化的关系[J].器官移植,2022,13(2):219-224.
[13] 吴小娅,戴康伟,曾瑞颖,等.同型半胱氨酸联合β2微球蛋白对H型高血压患者肾损害的早期预测价值[J].中国卫生检验杂志,2022,32(10):1228-1231.